Breaking new ground in healthcare data

  The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.  Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma.  “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).  Pharma, healthcare providers and health ministries have a golden opportunity to come together to drive innovation that will lead to new efficiencies, says the EVP& Head of Sanofi Pasteur.  The company ’s “groundbreaking” new approach to reengineering clinical trials by generating large sets of data in a prospective manner offers just such a way forward for the industry, he adds. “We have an urgent need to reinvent ourselves in the way we are conducting clinical trials. Pharma is a high-ri sk industry. We are making big bets. We have to find a way to come up with innovations at a lower cost.”  Insights at scale The way to improve the odds for pharma in trials, while also ultimately improving outcomes, is bringing digital technologies to bear via Machine Learning (ML)-based analysis of large-scale sets of health records data.  Sanofi is already busy trialling this approach. It is prospectively com...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news